Evidence map›Paper›PMID 38460943›Full record

Trial reportJournal of the American Medical Directors Association2024

Continuous Glucose Monitoring-Guided Insulin Administration in Long-Term Care Facilities: A Randomized Clinical Trial.

Thaer Idrees, Iris A Castro-Revoredo, Hyungseok D Oh, Monica D Gavaller, Zohyra Zabala, Emmelin Moreno, Bobak Moazzami, Rodolfo J Galindo, Priyathama Vellanki, Elena Cabb and 3 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Medical Directors Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Thaer IdreesDivision of Endocrinology, Department of Medicine, Emory University, Atlanta, GA, USA.
Iris A Castro-RevoredoDivision of Endocrinology, Department of Medicine, Emory University, Atlanta, GA, USA.
Hyungseok D OhDivision of Geriatrics, and Division of General Internal Medicine, Department of Medicine, Emory University, Atlanta, GA, USA.
Monica D GavallerDivision of Geriatrics, and Division of General Internal Medicine, Department of Medicine, Emory University, Atlanta, GA, USA.
Zohyra ZabalaDivision of Endocrinology, Department of Medicine, Emory University, Atlanta, GA, USA.
Emmelin MorenoDivision of Endocrinology, Department of Medicine, Emory University, Atlanta, GA, USA.
Bobak MoazzamiDivision of Endocrinology, Department of Medicine, Emory University, Atlanta, GA, USA.
Rodolfo J GalindoDivision of Endocrinology, Department of Medicine, Emory University, Atlanta, GA, USA.
Priyathama VellankiDivision of Endocrinology, Department of Medicine, Emory University, Atlanta, GA, USA.
Elena CabbDivision of Geriatrics, and Division of General Internal Medicine, Department of Medicine, Emory University, Atlanta, GA, USA.
Theodore M JohnsonDivision of General Internal Medicine, Department of Medicine, Emory University, Atlanta, GA, USA; Department of Family and Preventive Medicine, Emory University, Atlanta, GA, USA.
Limin PengEmory University Rollins School of Public Health, Atlanta, GA, USA.
Guillermo E UmpierrezDivision of Endocrinology, Department of Medicine, Emory University, Atlanta, GA, USA. Electronic address: geumpie@emory.edu.
Emory University · US

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
Developing statistical analysis and prediction tools for continuous glucose monitoring (CGM) use in hospitalized patients with diabetesR01DK136023 · NIDDK · EMORY UNIVERSITY · PI Limin Peng · 2024 to 2026
$1.1M
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 DiabetesK23DK123384 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALINDO, RODOLFO · 2020 to 2024
$934k
NCATS NIH HHS UL1 TR002378NIDDK NIH HHS K23 DK123384NIDDK NIH HHS P30 DK111024NIDDK NIH HHS R01 DK136023
6 · The paper itself

Abstract

objectivesTo evaluate the efficacy of real-time continuous glucose monitoring (rt-CGM) in adjusting insulin therapy in long-term care facilities (LTCF).

designProspective randomized clinical trial. SETTINGS AND

participantsInsulin-treated patients with type 2 diabetes (T2D) admitted to LTCF.

methodsParticipants in the standard of care wore a blinded CGM with treatment adjusted based on point-of-care capillary glucose results before meals and bedtime (POC group). Participants in the intervention (CGM group) wore a Dexcom G6 CGM with treatment adjusted based on daily CGM profile. Treatment adjustment was performed by the LTCF medical team, with a duration of intervention up to 60 days. The primary endpoint was difference in time in range (TIR 70-180 mg/dL) between treatment groups.

resultsAmong 100 participants (age 74.73 ± 11 years, 80% admitted for subacute rehabilitation and 20% for nursing home care), there were no significant differences in baseline clinical characteristics between groups, and CGM data were compared for a median of 17 days. There were no differences in TIR (53.38% ± 30.16% vs 48.81% ± 28.03%, P = .40), mean daily mean CGM glucose (184.10 ± 43.4 mg/dL vs 190.0 ± 45.82 mg/dL, P = .71), or the percentage of time below range (TBR) <70 mg/dL (0.83% ± 2.59% vs 1.18% ± 3.54%, P = .51), or TBR <54 mg/dL (0.23% ± 0.85% vs 0.56% ± 2.24%, P = .88) between rt-CGM and POC groups. CONCLUSIONS AND IMPLICATIONS: The use of rtCGM is safe and effective in guiding insulin therapy in patients with T2D in LTCF resulting in a similar improvement in glycemic control compared to POC-guided insulin adjustment.

Indexed as

Diabetes Mellitus, Type 2InsulinLong-Term CareAgedAged, 80 and overBlood GlucoseBlood Glucose Self-MonitoringContinuous Glucose MonitoringFemaleHumansHypoglycemic AgentsMaleMiddle AgedProspective StudiesBlood GlucoseHypoglycemic AgentsInsulinCGMContinuous glucose monitoringdiabetes mellitushospitalnursing homeskilled nursing facility

Identifiers

PMID38460943
PMCPMC11283256
OpenAlexW4392502146

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.